论文部分内容阅读
骨巨细胞瘤(Giant cell tumor of bone,GCT)是最常见骨肿瘤之一,但在细胞发生、病理诊断及临床治疗各方面都存在争议。早在1818年,Cooper首先描述了骨巨细胞瘤的组织学特征,在病理组织中以存在大量多核巨细胞为特点,曾长期被认为是良性肿瘤。后其转移和易复发等恶性特征逐渐被发现,1940年,Jaffe等在细胞学水平上重新描述了该瘤的组织学特征,排除了许多所谓变异性骨巨细胞瘤,如:动脉瘤样骨囊肿、软骨母细胞瘤等,并根据细胞变异情况,在病理学上分为三级,在临床实践中,人们发现其病理分级与临床表现并不一致。1980年美国肌肉骨关节肿瘤协会正式确定骨巨细胞瘤为低度恶性肿瘤。Enneking结合病变浸润范围和恶性程度
Giant cell tumor of bone (GCT) is one of the most common bone tumors, but it is controversial in all aspects of cellogenesis, pathological diagnosis and clinical treatment. As early as 1818, Cooper first described the histological features of giant cell tumor of bone, which was characterized by the presence of a large number of multinucleated giant cells in histopathological tissues. He had long been considered a benign tumor. After its metastasis and recurrence and other malignant features were gradually discovered, in 1940, Jaffe et al. at the cytological level re-delineated the histological features of the tumor, excluding many so-called variant giant cell tumor of the bone, such as: aneurysm bone Cysts, chondroblastomas, etc., and according to cell variability, are divided into three levels in pathology, in clinical practice, it was found that the pathological grading and clinical manifestations are not consistent. In 1980, the American Musculoskeletal and Joint Cancer Association formally established that giant cell tumor of bone is a low-grade malignant tumor. Enneking combined with lesion infiltration range and malignancy